Download Free Medical Beta-Lactam Antibiotics PowerPoint Presentation

Beta-Lactam Antibiotics PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Pharmacology, which is titled "Beta-lactam Antibiotics", to know about beta-lactam antibiotics.

Tags : Pharmacology, beta-lactam Antibiotics

Published on : Jul 18, 2021 | Views : 1901 | Downloads : 11

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Assoc. Prof. Ivan Lambev e-mail: itlambev@mail.bg www.medpharm-sofia.eu BETA-LACTAM ANTIBIOTICS
Slide 2-

Antimicrobial agents are among the most dramatic examples of the advances of modern medicine. Many infectious diseases once considered incurable and lethal now can be treated. The remarkably powerful and specific activity of antimicrobial drugs is due to their selective toxicity for targets that are either unique to microorganisms or much more important in them than in humans. Among these targets are bacterial and fungal cell wall-synthesizing enzymes, the bacterial ribosome, the enzymes required for nucleotide synthesis and DNA replication, the mechanism of viral replication, etc. The much older and less selective cytotoxic drugs are the antiseptics and disinfectants.
Slide 3-

ppt slide no 3 content not found
Slide 4-

ppt slide no 4 content not found
Slide 5-

ppt slide no 5 content not found
Slide 6-

ppt slide no 6 content not found
Slide 7-

Antiinfective agents may be classified according to their antimicrobial activity: 1. Antibacterial drugs (antibiotics and synthetic drugs) 2. Antiviral drugs 3. Antifungal drugs 4. Antiprotozoal drugs 5. Anthelmintic drugs 6. Insecticides for ectoparasites 7. Antiseptics and Disenfectant (Not are drugs) 8. Prepartaions for Disinsection (Not are drugs) 9. Prepartaions for Deratisation (Not are drugs) 10. Vaccines, Serums, and Immunoglobulins
Slide 8-

Antibacterial drugs have been classified broadly into: 1. bacteriostatic, i.e. those that act primarily by arresting bacterial multiplication, such as tetracyclines, chloramphenicol, macrolides, lincosamides, sulfonamides, etc. 2. bactericidal, i.e. those which act primarily by killing bacteria, such as penicillins, cephalosporins, aminoglycosides, isoniazid, rifampicin, quinolones, etc.
Slide 9-

ppt slide no 9 content not found
Slide 10-

ppt slide no 10 content not found
Slide 11-

30S: Aminoglycosides 30S: Tetracyclines 50S: Chloramphenicol 50S: Macrolides, Lincosamides 50S: Linezolide, Streptogramins Rifampicin Polymyxins ANTIBIOTICS – mechanism of action β-lactams, Glycopeptides
Slide 12-

Adverse Drug Reactions (ADRs) Antibacterial drugs may cause: ●direct host toxicity (aminoglycosides, peptides) ●toxic interactions with other drugs ●interference with protective effects of normal host microﬂora (by suppressing obligate anaerobes, for example selection or promotion of drug resistance ●tissue lesions at injection sites (tetracyclines) ●impairment of host immune or defense mechanisms (chloramphenicol)
Slide 13-

●reduced phagocytosis, and chemotactic activity of neutrophils (tetracyclines) ●inhibition of phagocytosis (aminoglycosides) ●hypersensitivity reactions (beta-lactams, aminosides, sulfonamides) ●hepatic microsomal enzyme induction (e.g. rifampin) or inhibition (e.g. chloramphenicol) that interferes with their own metabolism as well as that of concurrent medications,
Slide 14-

Selection or promotion of resistance Antibacterial agents do not cause bacteria to become resistant but their use preferentially selects resistant populations of bacteria. Some genes that code for resistance have been identiﬁed in bacterial cultures. The most clinically important for resistance are plasmids. They carry genes that may benefit survival of the organism (e.g. antibacterial resistance) transmitted from one bacterium to another.
Slide 15-

Plasmids are cytoplasmic genetic elements which transfer drug resistance to previously susceptible bacteria. Acquired resistance is not a problem in all bacteria. For example, Gram-positive bacteria (with some exceptions, incl. Staphylococcus spp) are often unable to acquire resistance plasmids (and thus acquire resistance through mutation, a slower process), whereas resistance is an increasing problem in many Gram-negative pathogens such as the Enterobacteriaceae.
Slide 16-

BETA-LACTAM ANTIBIOTICS (inhibitors of cell wall synthesis) Their structure contains a beta-lactam ring. The major subdivisions are: penicillins whose official names usually include or end in “cillin” (b) cephalosporins which are recognized by the inclusion of “cef” or “ceph” in their official names. (c) carbapenems (e.g. meropenem, imipenem) (d) monobactams (e.g. aztreonam) (e) beta-lactamase inhibitors (e.g. clavulanic acid, sulbactam).
Slide 17-

I. PENICILLINS A. FLEMING (1881–1955) Penicillin G - P. notatum (1929)
Slide 18-

Penicillium chrysogenum
Slide 19-

The cell wall completely surrounds the cytoplasmic membrane, maintains cell shape and integrity, and prevents cell lysis from high osmotic pressure. The cell wall is composed of a complex cross-linked polymer of polysaccharides and polypeptides, peptidoglycan (murein, mucopeptide). The polysaccharide contains alternating amino sugars, N-acetylglucosamine, and N-acetylmuramic acid. A five-amino-acid peptide is linked to the N-acetylmuramic acid sugar. This peptide terminates in D-alanyl-D-alanine.
Slide 20-

Penicillin-binding protein (PBP, an enzyme) removes the terminal alanine in the process of forming a cross-link with a nearby peptide. Cross-links give the cell wall its structural rigidity. Beta-lactam antibiotics covalently bind to the active site of PBPs. This inhibits the transpeptidation reaction, halting peptidoglycan synthesis, and the cell dies. Beta-lactams kill bacterial cells only when they are actively growing and synthesizing cell wall.
Slide 21-

ppt slide no 21 content not found
Slide 22-

NARROW SPECTRUM PENICILLINS Biosynthetic (natural) penicillins Antistaphylococcal beta-lactamase resistant penicillins BROAD SPECTRUM PENICILLINS Aminopenicillins Antipseudomonal penicillins - Carboxypenicillins - Ureidopenicillins
Slide 23-

Adverse effects The main hazard with the penicillins is allergic reaction. These include itching, rashes (eczematous or urticarial), fever, and angioedema. Rarely (about 1 in 10 000) there is anaphylactic shock which can be fatal (about 1 in 50 000 – 100 000 treatment courses). Allergies are least likely when penicillins are given orally and most likely with local application. Metabolic opening of the β-lactam ring creates a highly reactive penicilloyl group which polymerizes and binds with tissue proteins to form the major antigenic determinant. The anaphylactic reaction involves specific IgE antibodies which can be detected in the plasma of susceptible persons.
Slide 24-

Amoxicillin: rash 11 hours after administration
Slide 25-

There is cross-allergy between all the various forms of penicillin, probably due in part to their common structure, and in part to the degradation products common to them all. Partial cross-allergy exists between penicillins and cephalosporins (a maximum of 10%) which is of particular concern when the reaction to either group of antimicrobials has been angioedema or anaphylactic shock. Carbapenems and the monobactams apparently have a much lower risk of cross-reactivity.
Slide 26-

When the history of allergy is not clear and it is necessary to prescribe a penicillin, the presence of of IgE antibodies in serum is a useful indicator of reactions mediated by these antibodies, i.e. immediate (type 1) reactions. Additionally, an intradermal test for allergy may be performed; appearance of a flare and wheal reaction indicates a positive response. Only about 10% of patients with a history of “penicillin allergy” respond positively.
Slide 27-

Other (nonallergic) adverse effects include diarrhoea due to alteration in normal intestinal flora which may progress to Clostridium difficile-associated diarrhoea. Neutropenia is a risk if penicillins or other β-lactam antibiotics are used in high dose and usually for a period of longer than 10 days. Rarely penicillins cause anaemia, sometimes haemolytic, and thrombocytopenia or interstitial nephritis. Penicillins are presented as their sodium or potassium salts. Physicians should be aware of this unexpected source of sodium or potassium, especially in patients with renal or cardiac disease. Extremely high plasma penicillin concentrations cause convulsions. Co-amoxiclav, flucloxacillin, or oxacillin given in high doses for prolonged periods in the elderly may cause hepatic toxicity.
Slide 28-

1. NARROW SPECTRUM PENICILLINS a) Biosynthetic (natural) penicillins Benzylpenicillin (Penicillin G®) is used when high plasma concentrations are required. The short t1/2 (0.5 h) means that reasonably spaced doses have to be large to maintain a therapeutic concentration. The unusually large therapeutic ratio of penicillin allows the resulting fluctuations to be tolerable. Benzylpenicillin is eliminated by the kidney, with about 80% being actively secreted by the renal tubule and this can be blocked by probenecid.
Slide 29-

ppt slide no 29 content not found
Slide 30-

Penicillin G® is a drug of choice for infections caused by streptococci, meningococci, enterococci, penicillin- susceptible pneumococci, non-β-lactamase-producing staphylococci, T. pallidum and many other spirochetes, clostridium species, actinomyces, and other Gram- positive rods and non-β-lactamase-producing Gram- negative anaerobic organisms. Depending on the organism, the site, and the severity of infection, effective doses range is between 4 and 24 million units per day administered i.m. or i.v. in 4 to 6 divided doses. High-dose Penicillin G® Sodium can also be given as a continuous i. v. infusion.
Slide 31-

Phenoxymethylpenicillin Potassium (Penicillin-VK®) the oral form of penicillin, is indicated only in minor infections (e.g. tonsillitis) because of its relatively poor bioavailability, the need for dosing four times a day, and its narrow antibacterial spectrum. Benzathine penicillin and Procaine Penicillin G® maintain low but prolonged drug levels. A single i.m. injection of benzathine penicillin, 1.2 million units, is an effective treatment for β-hemolytic streptococcal pharyngitis; given once every 3–4 weeks, it prevents reinfection. Benzathine penicillin G, 2.4 million units i.m. once a week for 1–3 weeks, is effective in the treatment of syphilis.
Slide 32-

Penicilline G Sodium® Phenoxymethylpenicillin Potassium (Penicillin-VK®)
Slide 33-

Procaine penicillin G is rarely used nowadays because many strains are penicillin-resistant. b) Antistaphylococcal penicillins Isoxazolyl penicillins - Cloxacillin, Dicloxacillin - Flucloxacillin, Oxacillin Others - Methicillin - Nafcillin
Slide 34-

500 mg Flucloxacillin
Slide 35-

These semisynthetic penicillins are indicated for infection by beta-lactamase-producing staphylococci, although penicillin-susceptible strains of streptococci and pneumococci are also susceptible. Listeria, enterococci, and methicillin-resistant strains (MRS) of staphylococci are resistant. An isoxazolyl penicillin (cloxacillin, dicloxacillin, or oxacillin), 250–500 mg orally every 4 to 6 h (25 mg/kg/d for children), is suitable for the treatment of mild to moderate localized staphylococcal infections. All are relatively acid-stable but food interferes with their absorption, and the drugs should be administered 1 h before or after meals.
Slide 36-

ppt slide no 36 content not found
Slide 37-

2. BROAD-SPECTRUM PENICILLINS a) Aminopenicillins The aminopenicillins have identical spectrum and activity, but amoxicillin is better absorbed orally (70–90%). They are effective against streptococci, enterococci, and some Gram-negative organisms (including H. pylori) but have variable activity against staphylococci and are ineffective against P. aeruginosa. Amoxicillin and Ampicillin
Slide 38-

ppt slide no 38 content not found
Slide 39-

Amoxicillin, 500 mg 3 times daily, is equivalent to the same amount of ampicillin given four times daily. These drugs are given orally to treat urinary tract infections, sinusitis, otitis, and lower respiratory tract infections. Aminopenicillins are the most active of the oral beta-lactams against penicillin-resistant pneumococci and are the preferred beta-lactams for treating infections suspected to be caused by these resistant strains.
Slide 40-

Amoxicillin in VM
Slide 41-

Ampicillin (but not amoxicillin) is effective for shigellosis. Ampicillin, at dosages of 4–12 g/d i.v., is useful for treating serious infections caused by penicillin- susceptible organisms, including anaerobes, enterococci, L. monocytogenes, and beta-lactamase- negative strains of Gram-negative cocci and bacilli such as E. coli, and salmonella species. Non-beta- lactamase-producing strains of H. influenzae are generally susceptible. Many Gram-negative species produce beta-lactamases and are resistant.
Slide 42-

Carboxypenicillins Carbenicillin Ticarcillin Ureidopenicillins Azlocillin Mezlocillin Piperacillin b) Antipseudomonal penicillins These drugs retain activity against streptococci and possess additional effects against Gram-negative organisms, including various Enterobacteriaceae and Pseudomonas.
Slide 43-

Carbenicillin, the very first antipseudomonal carboxypenicillin, is obsolete. There are more active, better tolerated alternatives. A carboxypenicillin with activity similar to that of carbenicillin is Ticarcillin. It is less active than ampicillin against enterococci.
Slide 44-

The ureidopenicillins, piperacillin, mezlocillin, and azlocillin, are also active against selected Gram-negative bacilli, such as K. pneumoniae. Although supportive clinical data are lacking for superiority of combination therapy over single-drug therapy, because of the propensity of P. aeruginosa to develop resistance, an antipseudomonal penicillin is frequently used in combination with an aminoglycoside or fluoroquinolone for pseudomonal infections outside the urinary tract.
Slide 45-

II. CEPHALOSPORINS The nucleus of the cephalosporins, 7-aminocephalo- sporanic acid, bears a close resemblance to 6-amino- penicillanic acid. The intrinsic antimicrobial activity of natural cephalosporins is low, but the attachment of various R1 and R2 groups has yielded hundreds of potent compounds of low toxicity. Cephalosporins can be classified into four major groups or generations, depending mainly on the spectrum of their antimicrobial activity.
Slide 46-

7-Aminocephalosporanic acid nucleus
Slide 47-

Cephalosporins are similar to penicillins, but more stable to many bacterial beta-lactamases and therefore have a broader spectrum of activity. However, strains of E. coli and Klebsiella species expressing extended-spectrum beta-lactamases that can hydrolyze most cephalosporins are becoming a problem. Cephalosporins are not active against enterococci and L. monocytogenes. Klebsiella pneumoniae
Slide 48-

1. First-generation cephalosporins cefadroxil, cefazolin, cefalexin, cefalothin, cefapirin, cefradine These drugs are very active against Gram-positive cocci (such as pneumococci, streptococci, and Staphylococci). Cephalosporins are not active against methicillin-resistant strains of staphylococci. E. coli, K. pneumoniae, and P. mirabilis are often sensitive. Anaerobic cocci (e.g., peptococcus, peptostreptococcus) are usually sensitive, but Bacteroides fragilis is not. They do not cross BBB.
Slide 49-

Cefalexin p.o.
Slide 50-

Although the first-generation cephalosporins are broad spectrum and relatively nontoxic, they are rarely the drug of choice for any infection. Oral cephalosporins (cefalexin, cefadroxil, and cefradine) are absorbed from the gut to a variable extent. They may be used for the treatment of urinary tract infections, for staphylococcal, or for streptococcal infections including cellulitis or soft tissue abscess. However, oral cephalosporins should not be relied on in serious systemic infections.
Slide 51-

Cefazolin penetrates well into most tissues. It is a drug of choice for surgical prophylaxis. Cefazolin (i.m./i.v.) may be a choice in infections for which it is the least toxic drug (eg, K. pneumoniae) and in persons with staphylococcal or streptococcal infections with a history of penicillin allergy. Cefazolin does not penetrate the CNS and cannot be used to treat meningitis. Cefazolin is an alternative to an antistaphylococcal penicillin for patients who are allergic to penicillin.
Slide 52-

2. Second-generation cephalosporins cefaclor, cefamandole, cefprozil, cefotetan, cefuroxime, cefoxitin In general, they are active against organisms inhibited by first-generation drugs, but in addition they have extended Gram-negative coverage. Klebsiellae (including those resistant to cefalothin) are usually sensitive. Cefamandole, cefuroxime, and cefaclor are active against H. influenzae but not against serratia or B. fragilis. In contrast, cefoxitin, and cefotetan are active against B. fragilis and some serratia strains but are less active against H. influenzae. As with first-generation agents, none is active against enterococci or P. aeruginosa.
Slide 53-

Cefaclor, cefuroxime axetil, and cefprozil, can be given orally. The usual dosage for adults is 10 to 15 mg/kg/d in 2 to 4 divided doses; children should be given 20 to 40 mg/kg/d up to a maximum of 1 g/d. Except for cefuroxime axetil, these drugs are not predictably active against penicillin-resistant pneumococci and should be used cautiously, if at all, to treat suspected or proved pneumococcal infections. Cefaclor is more susceptible to β-lactamase hydrolysis compared with the other agents, and its usefulness is correspondingly diminished.
Slide 54-

The oral second-generation cephalosporins are active against beta-lactamase-producing H. influenzae or Moraxella catarrhalis and have been primarily used to treat sinusitis, otitis, or lower respiratory tract infections, in which these organisms have an important role. Because of their activity against anaerobes (including B. fragilis), cefoxitin or cefotetan, can be used to treat mixed anaerobic infections such as peritonitis or diverticulitis. Cefuroxime is used to treat community-acquired pneumonia because it is active against β-lactamase-producing H. influenzae or K. pneumoniae and penicillin-resistant pneumococci. Although cefuroxime crosses the BBB, it is less effective in the treatment of meningitis than ceftriaxone or cefotaxime, and should not be used.
Slide 55-

Cefuroxime Zinacef™
Slide 56-

Cefoxitin
Slide 57-

3. Third-generation cephalosporins cefixime, cefoperazone, cefotaxime, cefdinir, cefpodoxime, ceftriaxone Compared with second-generation agents, these drugs have expanded Gram-negative coverage, and some are able to cross the BBB. Third-generation drugs are active against Citrobacter, Serratia marcescens, and Providencia. They are also effective against β-lactamase-producing strains of Haemophilus and Neisseria. Ceftazidime and cefoperazone are the only two drugs with useful activity against P. aeruginosa.
Slide 58-

Neisseria Meningitidis Neisseria Gonorrhoea
Slide 59-

Like the second-generation drugs, third-generation cephalosporins are hydrolyzable by constitutively produced beta-lactamase, and they are not reliably active against enterobacter species. Serratia, Providencia, and Citrobacter also produce a chromosomally encoded cephalosporinase that, when constitutively expressed, can confer resistance to third-generation cephalosporins. Cefixime, cefdinir, and cefpodoxime are oral agents.
Slide 60-

Third-generation cephalosporins are used to treat a wide variety of serious infections caused by organisms that are resistant to most other drugs. Strains expressing extended-spectrum beta- lactamases, however, are not susceptible. Third-generation cephalosporins should be avoided in the treatment of Enterobacter infections. Ceftriaxone and cefotaxime are approved for the treatment of meningitis, including meningitis caused by pneumococci, meningococci, H. influenzae, and susceptible enteric Gram-negative rods, but not by L. monocytogenes.
Slide 61-

Ceftriaxone and cefotaxime are the most active cephalosporins against penicillin-resistant strains of pneumococci and are recommended for empirical therapy of serious infections that may be caused by these strains. Meningitis caused by highly penicillin-resistant strains of pneumococci (i.e., those susceptible only to penicillin MICs > 1 mcg/mL) may not respond even to these agents, and addition of vancomycin is recommended. Other potential indications include empirical therapy of sepsis of unknown cause in both the immunocompetent and the immunocompromised patient. In neutropenic, febrile immunocompromised patients, III-generation cepha- losporins are often used with an aminoglycoside.
Slide 62-

Ceftriaxone
Slide 63-

4. Fourth-generation cephalosporins cefepime, cefpirome Cefepime is more resistant to hydrolysis by chromosomal beta-lactamases (eg, those produced by enterobacter). It has good activity against P. aeruginosa, Enterobacteriaceae, S. aureus, and S. pneumoniae. Cefepime is highly active against Haemophilus and Neisseria. It penetrates well into the cerebrospinal fluid. It has good activity against most penicillin- resistant strains of streptococci, and it may be useful in the treatment of Enterobacter infections.
Slide 64-

III. CARBAPENEMS Doripenem Ertapenem Meropenem Tienam (imipenem/cilastatin)
Slide 65-

Imipenem has a wide spectrum with good activity against many Gram-negative rods, including P. aeru- ginosa, Gram-positive organisms, and anaerobes. It is resistant to most β-lactamases but not metallo- beta-lactamases. E. faecium, MRS of staphylococci, C. difficile and some others microorganisms are resistant. Imipenem is inactivated by dehydropeptidases in renal tubules, resulting in low urinary concen- trations. Consequently, it is administered together with an inhibitor of renal dehydropeptidase, Cilastatin, for clinical use.
Slide 66-

Meropenem is similar to imipenem but has slightly greater activity against Gram-negative aerobes and slightly less activity against Gram-positives. It is not significantly degraded by renal dehydropeptidase and does not require an inhibitor. Ertapenem is less active than meropenem or imipe- nem against P. aeruginosa and Acinetobacter species. It is not degraded by renal dehydropeptidase. Carbapenems penetrate body tissues and fluids well, including the cerebrospinal fluid. All are cleared renally, and the dose must be reduced in patients with renal insufficiency.
Slide 67-

Carbapenems are indicated for infections caused by susceptible organisms, e.g. P. aeruginosa, which are resistant to other available drugs and for the treatment of mixed aerobic and anaerobic infections. Carbapenems are active against many highly penicillin-resistant strains of pneumococci. A carbapenem is the beta-lactam of choice for the treatment of Enterobacter infections because it is resistant to destruction by the beta- lactamase produced by these organisms. Imipenem or meropenem with or without an aminoglycoside may be an effective treatment for febrile neutropenic patients.
Slide 68-

The most common adverse effects of carbapenems which tend to be more common with imipenem are nausea, vomiting, diarrhea, skin rashes, and reactions at the infusion sites. Excessive levels of imipenem in patients with renal failure may lead to seizures. Meropenem and ertapenem are less likely to cause seizures than imipenem. Patients allergic to penicillins may be allergic to carbapenems.
Slide 69-

IV. MONOBACTAMS Aztreonam Monobactams are drugs with a monocyclic β-lactam ring. They are relatively resistant to beta-lactamases and active against Gram-negative rods (including Pseudomonas and Serratia). They have no activity against Gram-positive bacteria or anaerobes. Aztreonam is given i.v. The half-life is 1–2 h and is greatly prolonged in renal failure. Penicillin-allergic patients tolerate aztreonam without reaction.
Slide 70-

V. BETA-LACTAMASE INHIBITORS Clavulanic acid Sulbactam Tazobactam ( ̶ )
Slide 71-

Resistance to penicillins and other beta-lactams is due to one of four general mechanisms: inactivation of the antibiotic by beta-lactamase; modification of the target PBPs; impaired penetration of the drug to the target PBPs; efflux of the drug from bacterial cells. Beta-lactamase production is the most common mechanism of resistance. Many hundreds of different beta-lactamases have been identified. Some, such as those produced by Staphylococcus aureus, Haemophilus spp., and Escherichia coli, are relatively narrow in substrate specificity, preferring penicillins to cephalosporins. They are called penicillinases and cephalosporinases.
Slide 72-

Other β-lactamases produced by P. aeruginosa and Enterobacter spp., and extended-spectrum beta-lactamases, hydrolyze both cephalosporins and penicillins. Carbapenems are highly resistant to hydrolysis by penicillinases and cephalosporinases but they are hydrolyzed by metallo-beta-lactamase and carbapenemases.
Slide 73-

Ampicillin, amoxicillin, ticarcillin, and piperacillin are also available in combination with one of several beta-lactamase inhibitors: clavulanic acid, sulbactam, or tazobactam. The addition of a beta- lactamase inhibitor extends the activity of these penicillins to include beta-lactamase-producing strains of S. aureus as well as some beta- lactamase-producing Gram-negative bacteria (E. coli, K. pneumoniae, P. aeruginosa, Proteus, H. influenzae).
Slide 74-

CO-AMOXICLAV (amoxicillin + clavulanic acid) Augmentin SULTAMICILLIN (ampicillin ( sulbactam) PIPERACILLIN + TAZOBACTAM Tazocin CEFOPERAZONE + SULBACTAM Sulperazon
Slide 75-

Antibacterial spectrum for amoxicillin- clavulanate * MRSA are resistant Co-Amoxiclave (BAN): Amoxicillin & Clavulanate Augmentin® Clavulox®
Slide 76-

Amoxicillin & Clavulanate (Augmentin®, Clavulox®) Clavulox® in VM (Veterinary Medicine!)
Slide 77-

Antibacterial spectrum for ticarcillin-clavulanate * MRSA are resistant
Slide 78-

ppt slide no 78 content not found